DK1817003T3 - Porøse silicium mikropartikler til lægemiddel levering til øjet - Google Patents

Porøse silicium mikropartikler til lægemiddel levering til øjet Download PDF

Info

Publication number
DK1817003T3
DK1817003T3 DK05819498.6T DK05819498T DK1817003T3 DK 1817003 T3 DK1817003 T3 DK 1817003T3 DK 05819498 T DK05819498 T DK 05819498T DK 1817003 T3 DK1817003 T3 DK 1817003T3
Authority
DK
Denmark
Prior art keywords
drug
particles
pores
porous
eye
Prior art date
Application number
DK05819498.6T
Other languages
English (en)
Inventor
William Freeman
Michael Sailor
Lingyun Cheng
Emily Anglin
Yang Yang Li
Frederique Cunin
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1817003T3 publication Critical patent/DK1817003T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (16)

1. En lægemiddel leveringsanordning til anvendel se ved den kontrollerede levering af et bestemt lægemiddel eller lægemidler til en bestemt placering i øjet, anordningen omfattende: porøse silicium- eller siliciumdioxidpartikler f mikrometerstørrelse med porer konfigureret og dimensioneret til i det mindste delvist at modtage mindst et lægemiddel deri ; og hvor partiklerne er egnede til at blive leveret ind i eller på øjet.
2. Anordning ifølge krav 1, hvor poremes indre vægge er kovalent modificeret således at bindingseffektiviteten af det mindst ene lægemiddel er forøget og/eller lægemiddelfrigivelsesprofiler af nævnte porer er blevet indstillet.
3. Anordning ifølge krav 2, hvor den kovalente modifikation af de indre vægge er udvalgt blandt gruppen omfattende funktionelle alkener, siliciumoxid, funktionelle or-ganohalider og metaller.
4. Anordning ifølge krav 1, hvor partiklerne er oxideret for at indfange lægemidlet eller lægemidlerne i porerne.
5. Anordning ifølge krav 1, hvor partiklerne er egnede til intraokulær injektion.
6. Anordning ifølge krav 1, hvor nævnte partikler har en monitorerbar optisk kode.
7. Anordning ifølge krav 1, hvor nævnte lægemiddel eller lægemidler omfatter en fra gruppen bestående af angiostatiske steroider, metalloproteinaseinhibitorer, et VEGF-bindende lægemiddel, pigmentepithelium-afledt faktor, et 8-mer peptidfragment af urokinase og dexamethason.
8. Fremgangsmåde til fremstilling af en anordning til kontrolleret lægemiddellevering til en placering i øjet omfattende: tilvejebringelse af en porøs nanostruktureret siliciumholdig template med porer konfigureret til at modtage et bestemt lægemiddel, opbrydning af templaten i partikler af mikrometerstørrelse, nævnte partikler er dimensioneret og konfigureret til at blive leveret ind i eller på en overflade af øjet; og lastning af enten templaten eller partiklerne af mikrometerstørrelse med lægemidlet,
9. Fremgangsmåde ifølge krav 8, hvor partiklerne er egnede til injektion intraokulært.
10. Fremgangsmåde ifølge krav 9, hvor partiklerne har et monitorerbart optisk respons afhængig af mængden af lægemiddel anbragt i porerne.
11. Fremgangsmåde ifølge krav 9, hvor partiklerne har et monitorerbart optisk respons afhængig af mængden af det tilstedeværende porøse materiale.
12. Fremgangsmåde ifølge krav 8, yderligere omfattende indfangning af lægemidlet eller lægemidlerne i porerne ved oxidation af den porøse template omkring lægemidlet eller lægemidlerne.
13. Fremgangsmåde ifølge krav 8, yderligere omfattende kovalent modifikation af poremes indre vægge for at forøge bindingseffektiviteten af det mindst ene lægemiddel og at indstille frigivelsesp.rofi.ler af porerne.
14. En porøs silicon- eller siliciumdioxidpartikel af mikrometerstørrelse med porer konfigureret og dimensioneret til i det mindste delvist at modtage mindst et lægemiddel deri; og hvor partiklen er egnet til at blive leveret ind i eller på øjet.
15. Partikel ifølge krav 14, hvor porernes indre vægge er ko valent modificeret således at bindingseffektiviteten af det mindst ene lægemiddel er forøget og/eller lægemiddelfrigivelsesprofiler af porerne er blevet indstillet.
16. Partikel ifølge krav 14, hvor nævnte lægemiddel er udvalgt blandt gruppen bestående af angiostatiske steroider, metalloproteinaseinhibitorer, et VEGF-bindende lægemiddel, pigmentepithelium-afiedt faktor, et 8-mer peptidfragment af urokinase og dexamethason.
DK05819498.6T 2004-10-29 2005-10-31 Porøse silicium mikropartikler til lægemiddel levering til øjet DK1817003T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62340904P 2004-10-29 2004-10-29
PCT/US2005/039177 WO2006050221A2 (en) 2004-10-29 2005-10-31 Porous photonic crystals for drug delivery to the eye

Publications (1)

Publication Number Publication Date
DK1817003T3 true DK1817003T3 (da) 2018-05-22

Family

ID=36319719

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05819498.6T DK1817003T3 (da) 2004-10-29 2005-10-31 Porøse silicium mikropartikler til lægemiddel levering til øjet

Country Status (5)

Country Link
US (3) US20090208556A1 (da)
EP (2) EP3381446A1 (da)
DK (1) DK1817003T3 (da)
ES (1) ES2669585T3 (da)
WO (1) WO2006050221A2 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US8765484B2 (en) 2002-02-07 2014-07-01 The Regents Of The University Of California Optically encoded particles
ES2669585T3 (es) 2004-10-29 2018-05-28 The Regents Of The University Of California Micropartículas porosas de silicio para la entrega de fármaco para el ojo
KR20160021307A (ko) 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
WO2010129545A2 (en) 2009-05-04 2010-11-11 Psivida Us, Inc. Porous silicon drug-eluting particles
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
EP3861969A1 (en) 2010-08-05 2021-08-11 ForSight Vision4, Inc. Injector apparatus for drug delivery
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
EP2635255B1 (en) 2010-11-01 2019-08-21 EyePoint Pharmaceuticals US, Inc. Bioerodible silicon-based devices for delivery of therapeutic agents
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
US10398592B2 (en) 2011-06-28 2019-09-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
PT2755600T (pt) 2011-09-16 2021-04-19 Forsight Vision4 Inc Aparelhos de troca de fluidos
FR2988721B1 (fr) 2012-03-27 2014-04-04 Centre Nat Rech Scient Nanoparticules de silicium poreux fonctionnalisees et leurs utilisations en therapie photodynamique
US20160002272A1 (en) * 2013-02-25 2016-01-07 The Regents Of The University Of California Surface functionalized porous silicon material and method of making thereof
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP2968571A4 (en) 2013-03-15 2016-09-07 Psivida Inc BIODEGRADABLE SILICONE BASED COMPOSITIONS FOR THE DELIVERY OF THERAPEUTIC AGENTS
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
RU2017105844A (ru) 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
CN110478119B (zh) 2014-11-10 2022-04-15 弗赛特影像4股份有限公司 可膨胀药物递送装置和使用方法
CN114533898B (zh) 2015-07-09 2025-07-01 加利福尼亚大学董事会 融合脂质体包被的多孔硅纳米颗粒
WO2017087902A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
WO2017181115A1 (en) 2016-04-14 2017-10-19 Spinnaker Biosciences, Inc. Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
CN111655206B (zh) 2017-11-21 2022-10-14 弗赛特影像4股份有限公司 用于可扩展端口递送系统的流体交换装置及使用方法
WO2019191132A1 (en) 2018-03-27 2019-10-03 The Regents Of The University Of California Drug delivery formulations
EP3714879A1 (en) 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles
GB201904336D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904337D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904334D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd Carrier system for preparing herbaceous extracts
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
JP2022132196A (ja) * 2021-02-26 2022-09-07 ナノ ターゲティング アンド セラピー バイオファーマ インコーポレイテッド 薬剤を後眼部に送達するための方法およびその使用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4701639A1 (en) 2023-05-31 2026-03-04 University of Tartu Molecules targeting infected tissues and methods of use thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2674743A (en) * 1950-09-21 1954-04-13 Romey A Gaiser Therapeutic, cosmetic, and corrective device
US3828777A (en) * 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
CA1311686C (en) * 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
RU2055555C1 (ru) * 1992-05-07 1996-03-10 Михаил Ефимович Маргус Устройство для лечения глазных болезней
GB9611437D0 (en) * 1995-08-03 1996-08-07 Secr Defence Biomaterial
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
US6322865B1 (en) 1998-07-13 2001-11-27 Patent Holding Company Hollow plastic article formed by a gas-assisted injection molding system
GB9815819D0 (en) * 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
GB9909996D0 (en) 1999-05-01 1999-06-30 Secr Defence Brit eland The SEE Sharp Kabushiki Kaisha 3-1 OPTICS - PATENTS 09/06/99 22:40:35 PAGE 40 NUMBER: 5747 30 JUNE 1999 cations For Patents retary of State for Defence, The Derivatized porous silicon
EP1175233B1 (en) 1999-05-01 2004-02-25 PSIMEDICA Limited Derivatized porous silicon
SE9903958D0 (sv) 1999-11-02 1999-11-02 Boerje Sellergren Porous materials for selective binding or transport of molecular guests
GB0008494D0 (en) * 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
GB2365769A (en) * 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
GB0104383D0 (en) * 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
US20020156274A1 (en) * 2001-03-16 2002-10-24 Terfloth Gerald J. Process for preparing maytansinol
US6815850B2 (en) * 2001-07-10 2004-11-09 International Business Machines Corporation Flux leakage barrier in fluid bearing for disk drive
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US20030060878A1 (en) * 2001-08-31 2003-03-27 Shadduck John H. Intraocular lens system and method for power adjustment
US7482168B2 (en) 2001-09-15 2009-01-27 The Regents Of The University Of California Photoluminescent polymetalloles as chemical sensors
US7042570B2 (en) 2002-01-25 2006-05-09 The Regents Of The University Of California Porous thin film time-varying reflectivity analysis of samples
US8765484B2 (en) * 2002-02-07 2014-07-01 The Regents Of The University Of California Optically encoded particles
EP1534202B1 (en) * 2002-06-05 2009-03-11 University Of Florida Research Foundation, Inc. Ophthalmic drug delivery system
US7942989B2 (en) * 2002-12-10 2011-05-17 The Regents Of The University Of California Porous silicon-based explosive
WO2004071949A2 (en) * 2003-02-13 2004-08-26 The Regents Of The University Of California Nanostructured casting of organic and bio-polymers in porous silicon templates
US7433811B2 (en) 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
US7318903B2 (en) * 2003-08-14 2008-01-15 The Regents Of The University Of California Photonic sensor particles and fabrication methods
GB0324483D0 (en) * 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
US20050181049A1 (en) * 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
GB2409924A (en) * 2004-01-06 2005-07-13 Psimedica Ltd Method of making a silicon-phosphorus composite
ATE469924T1 (de) * 2004-08-03 2010-06-15 Agency Science Tech & Res Polymer mit miteinander verbundenen poren zur arzneistoffzufuhr und verfahren
US7903239B2 (en) * 2004-10-19 2011-03-08 The Regents Of The University Of California Porous photonic crystal with light scattering domains and methods of synthesis and use thereof
ES2669585T3 (es) * 2004-10-29 2018-05-28 The Regents Of The University Of California Micropartículas porosas de silicio para la entrega de fármaco para el ojo
KR20160021307A (ko) * 2007-07-10 2016-02-24 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US9394369B2 (en) * 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
JP2015003902A (ja) * 2013-05-20 2015-01-08 杏林製薬株式会社 血管新生阻害剤

Also Published As

Publication number Publication date
US20090208556A1 (en) 2009-08-20
EP1817003A2 (en) 2007-08-15
US11241380B2 (en) 2022-02-08
US20180055765A1 (en) 2018-03-01
US8945602B2 (en) 2015-02-03
US20220000768A9 (en) 2022-01-06
US20130224302A1 (en) 2013-08-29
ES2669585T3 (es) 2018-05-28
WO2006050221A2 (en) 2006-05-11
WO2006050221A3 (en) 2007-10-11
EP1817003A4 (en) 2012-06-13
EP3381446A1 (en) 2018-10-03
EP1817003B1 (en) 2018-02-21

Similar Documents

Publication Publication Date Title
US11241380B2 (en) Porous photonic crystals for drug delivery to the eye
US12171877B2 (en) Materials and methods for delivering compositions to selected tissues
WO2019143293A1 (en) Self-implantable micro-drug-reservoirs for localized and controlled ocular drug delivery
WO2013169953A1 (en) Light degradable drug delivery system for ocular therapy
Gapeeva et al. Tetrapodal ZnO-based composite stents for minimally invasive glaucoma surgery
US20230166092A1 (en) Ultrasound mediated non-invasive drug delivery porous carriers
Zaman et al. Micro‐patterned drug delivery device for light‐activated drug release
HK1145652B (en) Materials and methods for delivering compositions to selected tissues
Sozaeva et al. Innovative Medicinal Contact Lenses: Controlled Drug Delivery Technologies in Ophthalmology